Navigation Links
Mediware Introduces Comprehensive Vision for Blood Center Technology
Date:4/14/2008

well as heart disease, stroke and cancer.

"We have a strong relationship with Mediware, and we are excited to be on the forefront of this exciting new vision," said Jackie Fredrick, BloodCenter of Wisconsin's President and Chief Executive Officer. "We have used LifeTrak to manage the clinical aspects of our blood center for about 6 years. With the addition of the dynamic capabilities brought forward by the IMS acquisition, we will be positioned to more effectively meet the needs of our hospital and community partners."

Mediware has more than 65 facilities using its LifeTrak donor management software to collect and test approximately 26% of the nation's blood supply. In November, the Company acquired IMS and began integrating IMS' powerful, web-based software with its existing clinical products to enable customers to dramatically improve donor recruitment and retention; drive coordinator loyalty and productivity; collection staff customer service and hospital order management.

"The addition of these new relationship-oriented technologies to Mediware's clinical capabilities creates a compelling vision and opens us to new levels of efficiency," said Janet Slater, Senior Vice President of Marketing and Business Development for BloodCenter of Wisconsin. "We will be able to more effectively recruit and retain donors, improve customer service and build better relationships with our hospital partners. Our partnership with Mediware assists us with providing our hospital customers access to the blood supplies they need."

Mediware has long been a leader in the clinical systems supporting blood management in independent blood centers and hospital transfusion centers. This includes many of the largest blood collection organizations and the most respected hospitals in the country.

Since the acquisition of IMS, Mediware has been aggressively integrating software and capabilities to streamline the effectiveness of blood centers, from donor recrui
'/>"/>

SOURCE Mediware Information Systems
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Philip Coelho Joins Mediware Board
2. Mediware Reports Second Quarter Fiscal 2008 Results
3. Mediware to Report Second Quarter 2008 Financial Results on Tuesday, February 5th
4. Mediware Completes Acquisition of Integrated Marketing Solutions
5. Texas Health and Human Services Commission Adopts Mediwares ClosedLoop(TM) Medication Management Strategy
6. Mediwares Transfusion Management Software Adopted by Four Additional Tenet Hospitals
7. Mediware Information Systems, Inc. Receives Notice from the Nasdaq Stock Market
8. Additional Top Tier Institutions Implement Mediwares HCLL(TM) Transfusion Management Software
9. Mediware Names Thomas K. Mann Chief Executive Officer
10. Richard Greco Joins Mediware Board
11. Polar Introduces Cost-Effective Solution to Reduce Heart Rate Data Cross-Talk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...Texas, Dec. 4 MiddleBroo...announced that it has opened its,administrative a... Germantown,facility will continue to house certa...,s research and development group. The newly leas...ed to house up to 60 employees as MiddleBrook,gro...
(Date:12/4/2008)... Mich., Dec. 4 BAPTIST HEALTH, a s...d the state,s largest health system, has,expanded...son Reuters -- a,solution that enabled the system...erventions and save more than $1 million. , ...ock campus show that,CareFocus prompts approximat...
(Date:12/4/2008)...ts similar to those seen with standard dose of dau.... 4 (HealthDay News) -- A high dose of the chemoth...ients with previously untreated acute myeloid leuk...ed by the U.S. National Cancer Institute (NCI) sho...ow. This study included 633 patients, aged 16 to 6...
(Date:12/4/2008)... AIDS Quilt Unites Leaders of Virginia, Maryland a... Nationally, Washington...g with AIDS in D.C., 82 percent are African Americ...isis in D.C. and the South, today,s Living Quilt r...ought together the leaders of the Virginia, Maryla...
Breaking Medicine News(10 mins):Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 2Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 3Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 4Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 2Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 3Health News:Higher Chemo Drug Dose Prolongs Lives of Leukemia Patients 2Health News:Southern AIDS Living Quilt Raises Awareness in Washington, D.C. 2Health News:Southern AIDS Living Quilt Raises Awareness in Washington, D.C. 3
... revealed that a surveillance programme designed t...s could cut the number of infections among patient...om Imperial College London and Hammersmith Hospita... Medical Journal, shows how the implementation of ...
... a law suit filed against sunscreen manufacturers ...eness of their products. // Dermatologists on the...screen. But some say that neither the sun protecti...ucts gives a clear picture to the consumers. Ultr...
... Hamidia Hospital here used an animal vaccine supp... to the suspension of a doctor //and storekeeper, ...lso blacklisted the Indore-based Nandini Laborator...he vaccine to the hospital. "It was just by chanc...
... union Unison has alleged that medical records of ...any errors that could cost the life of a patient. ...tries like India to save costs, the union said. H...ension", which means high blood pressure, instead ...
Other Medicine News:Health News:Surveillance Program for Haemodialysis Reduces Infection 2
(Date:12/4/2008)...lif., Dec. 4 Thoratec Co...vice-based mechanical circulatory support,therapi...id today that a,pre-specified interim analysis of...DT) pivotal trial shows that patients implanted wi...comes versus those in the control group who,were ...
(Date:12/4/2008)...e TLR8 Agonist to Advance to Clinical Trials , ...armaceuticals, Inc., a biopharmaceutical company f...tor 8 (TLR8) agonists for the treatment of cancer,...day that it has initiated a Phase I clinical trial...atment of cancer. The multi-center clinical trial...
(Date:12/3/2008)...t-line data demonstrating potential in newly diagn...emia to be featured in two oral sessions at ASH ,...for chronically transfused patients by significant..., , - New long-term data from major indepen...imal post-surgery treatment strategy, Femara vs. t...
(Date:12/3/2008)...reatment alleviates long-term anemia and organ dam...ns , , MEMPHIS, Tenn., Dec. 3 /PRNewswire-...corrective gene into mouse blood cells, scientists...eviated sickle cell disease pathology. In their st... showed essentially no difference from normal mice...
Breaking Medicine Technology:Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial 2Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial 3Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial 4VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 2Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 3Just in Time for Winter a New Berry Thats Good for Your Health 3302 1Just in Time for Winter a New Berry Thats Good for Your Health 3302 2Just in Time for Winter a New Berry Thats Good for Your Health 3302 3Novel Mass Spectrometry based Assay Reveals Degradation and Low Levels of Bioactive B type Natriuretic Peptide 28BNP 29 in Patients with Heart Failur 8323 1Novel Mass Spectrometry based Assay Reveals Degradation and Low Levels of Bioactive B type Natriuretic Peptide 28BNP 29 in Patients with Heart Failur 8323 2China Biologic Products Enters Into Agreement to Acquire 35 25 Interest in Xian Huitian Blood Products Co Ltd and Introduces Preliminary Guidance f 8318 1China Biologic Products Enters Into Agreement to Acquire 35 25 Interest in Xian Huitian Blood Products Co Ltd and Introduces Preliminary Guidance f 8318 2China Biologic Products Enters Into Agreement to Acquire 35 25 Interest in Xian Huitian Blood Products Co Ltd and Introduces Preliminary Guidance f 8318 3China Biologic Products Enters Into Agreement to Acquire 35 25 Interest in Xian Huitian Blood Products Co Ltd and Introduces Preliminary Guidance f 8318 4China Biologic Products Enters Into Agreement to Acquire 35 25 Interest in Xian Huitian Blood Products Co Ltd and Introduces Preliminary Guidance f 8318 5PAREXEL Consulting Quantifies Speed to Market 3A First Cycle Approval for NME Produces 24640 Million in Incremental Revenue on Average 8313 1PAREXEL Consulting Quantifies Speed to Market 3A First Cycle Approval for NME Produces 24640 Million in Incremental Revenue on Average 8313 2PAREXEL Consulting Quantifies Speed to Market 3A First Cycle Approval for NME Produces 24640 Million in Incremental Revenue on Average 8313 3PAREXEL Consulting Quantifies Speed to Market 3A First Cycle Approval for NME Produces 24640 Million in Incremental Revenue on Average 8313 4PAREXEL Consulting Quantifies Speed to Market 3A First Cycle Approval for NME Produces 24640 Million in Incremental Revenue on Average 8313 5
... build-up of calcium,plaque in the arteries means ...rt disease in multiple ethnic groups, according to...osclerosis (MESA),funded by the National Heart, Lu... of Health. Previous studies have shown that,incre...risk of,heart disease events and deaths in Caucasi...
...roved Outcomes in Carotid,Artery Stenting, ABBOTT ...--,Positive 30-day results from two Abbott studies...th positive results by,physicians with a variety o...l trial) settings in patients who are not favorabl... first 1,500,patients enrolled in EXACT (Emboshiel...
Other Medicine Technology:Calcium Plaque Build-up in the Arteries Leads to Coronary Heart,Disease in Multi-Ethnic Groups 2Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and,Effective Treatment to Reduce Risk of Stroke 2Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and,Effective Treatment to Reduce Risk of Stroke 3Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and,Effective Treatment to Reduce Risk of Stroke 4
Hydrophobic PE filter without self-sealing additives, permits sample recovery after accidental over-pipetting. All filters are sterile (to USP, DAB, Ph.Eur. standards) and PCR clean (free from human
... Aerosol Resistant Tips offer a safe alternative t...are designed for applications such as PCR(a), pipe...n addition, ART Tips are excellent for tissue cult...studies. ART Tips prevent aerosol contaminants and...
...ntGard Low Binding 0.5l - 10l Eppendorf Barrier Ti...ng technology that significantly reduces the amoun... filter tips are advertised as low retention, whic... pipet tip. However, AvantGard also focuses on low...
10 L, Racked, Filtered, Pre-sterilized, 96 tips/rack Recommended for 5 & 10 L pipettes. Ideal for pipetting into long, narrow tubes or deep well plates.
Medicine Products: